molecules of the month

FT-2102 (olutasidenib)

allosteric mutant-selective IDH1 inhibitor

oral, in clinical development

from SBDD of prior mIDH inhibitor

J. Med. Chem. 2020, 63, 1612-1623

FORMA Therapeutics, Watertown, MA

FT-2102 (olutasidenib)
1 min read

FT-2102 (olutsidenib) (FORMA oral allosteric mutant-selective IDH1 inhibitor clinical candidate)

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: